Novel Ultrasound Based Viscoelasticity Imaging Tool to Reduce Invasive Breast Lesion Biopsy Rate

项目摘要/摘要 拉什河研究公司与梅奥诊所合作，提议开发一种新颖的用户- 友好的非侵入性诊断工具，可用于测量乳房组织的粘弹性 将乳房病变定性为良性或恶性。乳腺癌是第二大常见的恶性肿瘤。 在美国女性中，癌症是导致女性癌症相关死亡的主要原因。诊断 旅程通常涉及多项筛查和后续诊断技术。以下是积极的结果 根据这些侵入性较小的诊断，通常会进行活组织检查。然而，大多数活组织检查是在 使用典型筛查方法筛查乳腺癌呈阳性的女性被发现是良性的。这 导致没有患癌症的女性经历巨大的身体、情感和经济负担。 此外，在美国，可能不必要的良性活检每年的费用超过20亿美元。 各州。拟议中的测量组织粘弹性的新工具将提供有关世卫组织的定量反馈 应该接受活组织检查以及肿瘤的2D彩色图像。这种新型工具使用现有的超声波 机器和超声波头，可以在与诊断超声相同的预约时间使用 同一台机器。需要机械附件来提供自动的、力控制的、动态的 轴向压缩，并将在这个项目中开发和测试使用模体。这项技术将 为医生提供更好的决策工具，并帮助妇女避免不必要的活检。

Project Summary/Abstract Rush River Research Corporation, in collaboration with the Mayo Clinic, proposes to develop a novel, user- friendly, non-invasive diagnostic tool to measure viscoelasticity of breast tissue which can be used to characterize breast lesions as benign or malignant. Breast cancer is the second most common malignancy among women in the United States and a leading cause of cancer-related deaths in females. The diagnostic journey typically involves multiple screenings and follow-on diagnostics techniques. Following positive results from these less invasive diagnostics, a biopsy is typically performed. However, most biopsies performed on women who screened positive for breast cancer using typical screening methods are found to be benign. This results in a large physical, emotional, and economic burden experienced by women who do not have cancer. Additionally, the cost of potentially unwarranted benign biopsies is more than $2 billion annually in the United States. The proposed new tool to measure viscoelasticity of tissue will provide quantitative feedback on who should receive a biopsy as well as a 2D colormap image of the tumor. The novel tool uses existing ultrasound machines and ultrasound heads and can be done at the same appointment as a diagnostic ultrasound using the same machine. A mechanical attachment is required to provide an automated, force-controlled, dynamic, axial compression and will be developed and tested using phantoms in this project. This technology will provide physicians with a better tool for decision-making and help women avoid unnecessary biopsies.